These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 36292577)

  • 21. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
    Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
    Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
    Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations.
    Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Fanale D; Corsini LR; Brando C; Randazzo U; Bono M; Pedone E; Perez A; Sciacchitano R; Cancelliere D; Piraino P; Giurintano A; Bazan Russo TD; Ferraro P; Rinaldi G; Spinnato V; Gennusa V; Pernice G; Vieni S; Pantuso G; Russo A; Bazan V
    Front Oncol; 2024; 14():1414343. PubMed ID: 38974244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies.
    Plowman JN; Matoy EJ; Uppala LV; Draves SB; Watson CJ; Sefranek BA; Stacey ML; Anderson SP; Belshan MA; Blue EE; Huff CD; Fu Y; Stessman HAF
    HGG Adv; 2024 Jul; 5(3):100306. PubMed ID: 38734904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
    Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
    J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
    Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
    Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline TP53 mutational spectrum in French Canadians with breast cancer.
    Arcand SL; Akbari MR; Mes-Masson AM; Provencher D; Foulkes WD; Narod SA; Tonin PN
    BMC Med Genet; 2015 Apr; 16():24. PubMed ID: 25925845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    Vietri MT; D'Elia G; Caliendo G; Resse M; Casamassimi A; Passariello L; Albanese L; Cioffi M; Molinari AM
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
    BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-gene panel analysis in BRCA1/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: Real-world data from a single institution.
    Nakahara M; Ushiama M; Tanabe N; Gotoh M; Sakamoto H; Yoshida T; Hirata M
    J Obstet Gynaecol Res; 2024 Sep; 50(9):1591-1597. PubMed ID: 39077936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.
    de Freitas Ribeiro AA; Junior NMC; Dos Santos LL
    Eur J Med Res; 2024 Mar; 29(1):187. PubMed ID: 38504328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
    Santonocito C; Scapaticci M; Guarino D; Bartolini A; Minucci A; Concolino P; Scambia G; Paris I; Capoluongo E
    Breast; 2017 Dec; 36():74-78. PubMed ID: 29020660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.